AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 132 min read$INDV

Heidbreder Christian sold $765K of INDV

Heidbreder Christian (Chief Scientific Officer) sold 18,586 shares of Indivior Pharmaceuticals, Inc. (INDV) at $41.14 ($0.76M total) on 2026-07-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Heidbreder Christian
Published Jul 13, 2026, 8:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 13, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$INDV
Neutral
medium confidence
Mentioned
$INDV
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INDVNeutralLow
01

Why it matters

The disclosure updates the insider activity record and may influence sentiment, but it does not provide new operational, clinical, or financial information about Indivior.

02

Market read

Traders may monitor for patterns in subsequent insider filings, but this specific transaction is likely routine given the 10b5-1 plan.

03

What to watch

10b5-1 plans can produce sales regardless of company outlook; without additional context (e.g., multiple consecutive sales, option exercises, or purchases), signal quality is low.

Relevance 4/10Novelty 5/10Timing: after-hours/next-session read-through from a newly filed Form 4 (filed 2026-07-13)

Background

The filing is an SEC Form 4 insider transaction by Indivior’s Chief Scientific Officer, reported as an open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$INDVNeutralMedium confidence
Context

Indivior CSO Christian Heidbreder sold 18,586 shares on 2026-07-10 for about $764,628 under a 10b5-1 plan.

Expected impact

Likely limited, short-lived impact unless follow-on filings show unusual acceleration or size.

Evidence & confidence

Form 4 shows an open-market sale by an officer with a pre-arranged 10b5-1 plan; such sales are typically less informative than unscheduled transactions.

Market effects

Sector

Minimal; insider selling by a single pharma executive rarely changes sector risk materially.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A large officer sale can still be interpreted as confidence in liquidity needs or portfolio rebalancing, but traders may overreact despite the 10b5-1 structure.

Key entities

  • issuer
    Indivior Pharmaceuticals, Inc.

    Subject of the Form 4 insider sale disclosure (INDV).

  • insider
    Heidbreder Christian

    Chief Scientific Officer who sold 18,586 shares on 2026-07-10.

  • trading mechanism
    10b5-1 plan

    Pre-arranged plan indicating the sale schedule was set in advance.

Read at source← All news

Related articles

AUG 4
$SUPNMedAI 8/10

$1.8bn merger unites Supernus and Indivior

Supernus Pharmaceuticals and Indivior agreed to merge in a deal valued at about $1.8 billion. Indivior shareholders will receive 0.2683 Supernus shares each, a stated ~58% premium. Supernus shareholders will own ~58% and Indivior ~42%. Closing is expected in H2 2026, pending approvals, with ~$125 million annual cost synergies by end-2027.

bioxconomy.com3 min
AUG 4
$INDVMedAI 9/10

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

Indivior (INDV) agreed to a tax-free, all-stock merger with Supernus (SUPN). Indivior shareholders will own about 56.5% and Supernus 43.5%. The combined CNS-focused company is expected to close in Q4 2026 and trade on Nasdaq under SUPN. Pro forma: ~$2.2B revenue, $888M adjusted EBITDA, $125M synergies. Indivior Q2 2026: adj. EPS $1.15, revenue $343M.

finance.yahoo.com7 min
AUG 4
$SUPNMedAI 8/10

Supernus and Indivior merge to create scaled, CNS-focused entity - Pharmaceutical Technology

Supernus Pharmaceuticals and Indivior are planning an all-stock merger to form a CNS-focused biopharma. The deal is expected to produce pro forma net revenue of $2.2bn and about $125m in annual cost synergies. Supernus brings Qelbree and Gocovri; Indivior brings Sublocade, Suboxone and Opvee. If completed in Q4 2026, the combined firm will trade as SUPN on Nasdaq.

pharmaceutical-technology.com4 min
AUG 3
$SUPNMedAI 8/10

Why Supernus Pharmaceuticals Stock Topped the Market Today

Supernus Pharmaceuticals (SUPN) rose 3% after announcing a definitive, tax-free all-stock merger with Indivior Pharmaceuticals (INDV), expected to close in Q4 and subject to approvals. The combined portfolio would include 11 FDA-approved drugs. Supernus reported Q2 revenue up 32% to just over $219M, but a net loss of over $58M and a miss versus EPS profit estimates.

fool.com5 min
AUG 3
$INDVMedAI 8/10

Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc Appoints Jack A. Khattar as Chief Executive Officer of Supernus, Inc

Indivior Pharmaceuticals and Artemis Merger Sub agreed to merge with Supernus Pharmaceuticals, with Supernus as the surviving company and a wholly owned subsidiary of Indivior. After the deal, Indivior will be renamed Supernus. Jack A. Khattar will become CEO and CFO Timothy C. Dec will serve as CFO, effective at closing.

marketscreener.com4 min